Alpha lactalbumin oleic acid - Hamlet Pharma AB
Alternative Names: Alpha 1H; HAMLET; Human alpha-lactalbumin made lethal to tumoursLatest Information Update: 28 Jul 2026
At a glance
- Originator Hamlet Pharma AB
- Developer Hamlet Pharma AB; Neurochase
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Bladder cancer
- No development reported Brain cancer; Cancer; Colorectal cancer; Glioblastoma; Papilloma; Skin cancer
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for preclinical development in Brain-cancer in Sweden (Infusion)
- 22 Jun 2026 Hamlet Pharma AB and University of Iowa agree co-develop Alpha lactalbumin oleic acid forBladder cancer
- 22 Jun 2026 Hamlet Pharma AB submits new clinical trial protocol amendment to the US FDA for Bladder cancer